Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Affimed N.V.
  6. News
  7. Summary
    AFMD   NL0010872420

AFFIMED N.V.

(AFMD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Affimed N : Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer

10/04/2021 | 05:44am EST

Heidelberg, Germany - Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced that three abstracts with preclinical data of its innate cell engagers have been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 10-14, 2021.

Abstract details:

Title: Tetravalent, bispecific innate cell engager AFM24 enhances macrophage mediated tumor cell phagocytosis

Abstract ID: 880

Authors: Sheena Pinto, Susanne Wingert, Jens Pahl, Armin Beez, Sabrina Purr, Uwe Reusch, Arndt Schottelius and Joachim Koch

Title: Enhanced antibody-mediated phagocytosis and antibody-mediated cell cytotoxicity using tetravalent, bispecific innate cell engagers (ICE) in 3D spheroids

Abstract ID: 881

Authors: Sheena Pinto, Savannah Jackson, Julia Knoch, Christian Breunig, Arndt Schottelius and Joachim Koch

Title: The bispecific innate cell engagers AFM13 (CD30/CD16A) and AFM24 (EGFR/CD16A) increase the fraction of tumor target-responsive NK cells and boost serial killing

Abstract ID: 894

Authors: Chiara Zambarda, Karolin Guldevall, Christian Breunig, Damien Toullec, Jacopo Fontana, Sheena Pinto, Jens Pahl, Susanne Wingert, Joachim Koch and Bjorn Onfelt

The full abstracts will be released on November 9, 2021 at 8 a.m. EST.

For more details about the SITC Virtual Annual Meeting please visit: https://www.sitcancer.org/2021/home.

About Affimed N.V.

Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors, enabling a broad pipeline of wholly-owned and partnered single agent and combination therapy programs. The ROCK platform predictably generates customized innate cell engager (ICE) molecules, which use patients' immune cells to destroy tumor cells. This innovative approach enabled Affimed to become the first company with a clinical-stage ICE. Headquartered in Heidelberg, Germany, with offices in New York, NY, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients' lives. For more about the company's people, pipeline and partners, please visit: www.affimed.com.

Contact:

Affimed Investor

Alex Fudukidis

Head of Investor Relations

E-Mail: a.fudukidis@affimed.com

Tel: +1 (917) 436-8102

Media

Mary Beth Sandin

Vice President

Marketing and Communications

E-Mail: M.Sandin@affimed.com

Tel: +1 (484) 888-8195

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about AFFIMED N.V.
11/22Health Care Stocks Finishing Mixed This Afternoon
MT
11/22Health Care Stocks Drifting Near Unchanged Mark Monday
MT
11/22Affimed NV's Innate Cell Engager Achieves 100% Objective Response Rate In Phase 1/2 Lym..
MT
11/22Wall Street Sees Upbeat Open as Potential China Easing Lifts Sentiment
MT
11/22Top Premarket Gainers
MT
11/22AFFIMED N : Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of C..
PU
11/22Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Co..
GL
11/22Affimed Announces Interim Clinical Results from the Investigator-Initiated Phase 1-2 St..
CI
11/17Berenberg Bank Initiates Coverage on Affimed With Buy Rating, $11 Price Target
MT
11/16AFFIMED N : Jefferies London Healthcare Conference 2021 - Virtual
PU
More news
Analyst Recommendations on AFFIMED N.V.
More recommendations
Financials
Sales 2021 38,1 M 43,2 M 43,2 M
Net income 2021 -56,0 M -63,3 M -63,3 M
Net cash 2021 172 M 195 M 195 M
P/E ratio 2021 -13,1x
Yield 2021 -
Capitalization 758 M 858 M 858 M
EV / Sales 2021 15,4x
EV / Sales 2022 12,6x
Nbr of Employees 153
Free-Float 97,2%
Chart AFFIMED N.V.
Duration : Period :
Affimed N.V. Technical Analysis Chart | AFMD | NL0010872420 | MarketScreener
Technical analysis trends AFFIMED N.V.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Last Close Price 6,16 €
Average target price 11,38 €
Spread / Average Target 84,8%
EPS Revisions
Managers and Directors
Adolf Hoess Chief Executive Officer
Angus W. Smith Chief Financial Officer
Thomas O. Hecht Chairman-Supervisory Board
Andreas Harstrick Chief Medical Officer
Arndt Schottelius Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
AFFIMED N.V.19.76%858
GILEAD SCIENCES, INC.20.61%88 146
BIONTECH SE326.89%84 049
REGENERON PHARMACEUTICALS33.17%67 266
WUXI APPTEC CO., LTD.24.40%64 416
VERTEX PHARMACEUTICALS-22.32%46 678